A Clinical Question That Keeps Surfacing: GLP-1 vs "GLP-3"
A clinician reviewing a patient's supplement history sees "GLP-3 peptide" listed alongside semaglutide and asks the obvious question: what receptor system is this actually acting on? The answer, checked against the peer-reviewed endocrine literature, is that no validated endogenous GLP-3 hormone or receptor exists. Proglucagon processing in the intestinal L-cell produces glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) — that is the full recognized set. "GLP-3" is a term that circulates primarily in commercial peptide marketing, and it is used inconsistently across suppliers.
Where the term does map onto something real, it is typically shorthand for next-generation multi-receptor agonist peptides — molecules engineered to activate the GLP-1 receptor alongside GIP and/or glucagon receptors. Retatrutide is the clearest example: a single peptide with agonist activity at GLP-1, GIP, and glucagon receptors, studied in a completed Phase 2 program (NCT04881292) and reported in the New England Journal of Medicine (Jastreboff et al., 2023, PMID 37366315).
This article treats the comparison the way the underlying data actually supports it: GLP-1 receptor monoagonism (semaglutide) versus multi-receptor agonism (tirzepatide as a dual agonist, retatrutide as a triple agonist), since that is the substantive pharmacological question hiding behind the "GLP-1 vs GLP-3" framing patients and researchers are searching for.
GLP-1 Receptor Pharmacology: What the Binding Data Shows
The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic beta cells, in the hypothalamus, and in gastric tissue. Semaglutide activates this receptor with an EC50 in the low nanomolar range in cAMP accumulation assays using HEK293 cells expressing the human GLP-1 receptor, with a half-life extended to roughly 165-184 hours via albumin binding through a C18 fatty diacid side chain (Lau et al., J Med Chem 2015, PMID 26308095). That extended half-life is what permits once-weekly dosing.
Downstream, GLP-1 receptor activation increases intracellular cAMP, potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic satiety centers. The glucose-dependence of the insulin effect is mechanistically important: it explains why GLP-1 receptor agonists carry a comparatively low intrinsic hypoglycemia risk when used without concurrent sulfonylureas or insulin.
Tirzepatide adds GIP receptor agonism to this profile. Coskun et al. (Mol Metab 2018, PMID 30017785) characterized tirzepatide as a GIP receptor-biased dual agonist, with in-vitro data suggesting the GIP component may contribute to improved insulin sensitivity and adipose tissue effects independent of the GLP-1 pathway. Retatrutide extends the same logic one receptor further, adding glucagon receptor agonism, which increases energy expenditure but also carries a documented association with more pronounced early gastrointestinal symptoms in Phase 2 data.
Understanding receptor pharmacology matters clinically because it predicts, rather than merely describes, the tolerability and efficacy differences observed in trials — a pattern discussed further below.Head-to-Head Efficacy: HbA1c Outcomes Across Trials
SURPASS-2 (NCT03987919) remains the most direct randomized comparison available between a GLP-1 monoagonist and a dual agonist in type 2 diabetes. Over 40 weeks, tirzepatide at 5 mg, 10 mg, and 15 mg produced mean HbA1c reductions of 2.01, 2.24, and 2.30 percentage points respectively, compared with 1.86 points for semaglutide 1 mg (Frías et al., NEJM 2021, PMID 34170647). All three tirzepatide doses met statistical superiority versus semaglutide on the primary endpoint (p<0.001 for the 10 mg and 15 mg doses).
No equivalent randomized head-to-head trial exists comparing a GLP-1 monoagonist against a triple agonist in a type 2 diabetes population specifically — the retatrutide Phase 2 program enrolled participants with obesity, with type 2 diabetes as a secondary population in a related sub-study, not the primary indication. That distinction matters: efficacy figures for retatrutide in diabetes should be read as preliminary rather than confirmatory.
Within that Phase 2 program, retatrutide 12 mg produced HbA1c reductions in participants with type 2 diabetes and obesity of approximately 2.0 percentage points at 36 weeks in a substudy reported alongside the primary weight-loss results (PMID 37366315). Baseline HbA1c, trial duration, and background medication use all differed enough from SURPASS-2 that cross-trial numeric comparison should be treated as directional, not definitive, pending head-to-head Phase 3 data.
Weight Outcomes: Where the Multi-Agonist Signal Is Largest
Weight change is where the separation between monoagonist and multi-agonist classes is most consistent across the available trials. STEP 1 (NCT03548935) reported a mean 14.9% body weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021, PMID 33667864). SURMOUNT-1 (NCT04184622) reported mean weight reductions of 15.0%, 19.5%, and 20.9% for tirzepatide 5 mg, 10 mg, and 15 mg respectively at 72 weeks (Jastreboff et al., NEJM 2022, PMID 35658024).
The retatrutide Phase 2 trial reported a mean 17.5% weight reduction at the 12 mg dose at 48 weeks — a shorter trial duration than SURMOUNT-1 but a steeper early trajectory, with the weight-loss curve not yet plateaued at trial end (PMID 37366315). Some participants at the highest dose exceeded 24% total body weight reduction, though this reflects a subset, not the trial mean.
Two caveats belong in any responsible reading of these numbers. First, trial populations differ in baseline BMI, diabetes status, and background therapy, which affects the weight-loss ceiling independent of drug mechanism. Second, none of these trials were designed as a formal three-arm superiority comparison across all three compounds, so the apparent dose-response gradient from monoagonist to dual to triple agonist is a pattern across separate trials, not a statistically confirmed ranking.
Safety and Tolerability: Comparing Adverse Event Profiles
Gastrointestinal adverse events dominate the safety signal across every GLP-1 pathway compound studied to date. In STEP 1, nausea was reported in 44.2% of the semaglutide group versus 16.1% with placebo, with diarrhea at 30.3% versus 15.5%. Discontinuation due to adverse events occurred in 7.0% of the semaglutide arm.
SURMOUNT-1 reported broadly similar GI event rates for tirzepatide, with nausea ranging from 24-33% across doses and discontinuation due to adverse events between 4.3% and 7.1% depending on dose. Notably, these rates were not dramatically higher than semaglutide's despite the added GIP mechanism, suggesting GIP co-agonism does not substantially compound GLP-1-driven GI symptoms in this population.
Retatrutide's Phase 2 data showed a somewhat different pattern: GI adverse events, particularly at higher doses, were reported at rates numerically higher than either semaglutide or tirzepatide monotherapy/dual-agonist trials, with nausea approaching 50% at the top dose during titration. Whether this reflects the glucagon receptor component, faster titration schedules used in the Phase 2 protocol, or trial-specific factors is not yet resolved and warrants dedicated dose-titration studies before firm conclusions are drawn.
Across all three compounds, serious adverse events related to pancreatitis, gallbladder disease, and injection-site reactions were reported at low single-digit percentages, consistent with the established GLP-1 receptor agonist class safety profile documented in FDA prescribing information.
Trial Design Differences That Affect How These Numbers Should Be Read
Cross-trial comparison of semaglutide, tirzepatide, and retatrutide data requires attention to design features that materially affect outcome magnitude. Trial duration varies from 40 weeks (SURPASS-2) to 72 weeks (SURMOUNT-1), and weight-loss and HbA1c curves for GLP-1 pathway agents typically have not fully plateaued even at those endpoints, meaning longer trials tend to report larger effect sizes independent of relative drug potency.
Population selection also differs. SURPASS-2 enrolled participants with type 2 diabetes and a mean baseline HbA1c around 8.3%. SURMOUNT-1 excluded diabetes as an inclusion criterion, enrolling participants with obesity or overweight and weight-related comorbidities. Retatrutide's Phase 2 trial enrolled a mixed population with a diabetes substudy analyzed separately. These differences in baseline metabolic status change both the ceiling and floor for observed effect sizes.
Attrition rates matter for interpreting how representative the completer-population results are. SURMOUNT-1 reported a completion rate above 85% across arms; the retatrutide Phase 2 trial's dose-escalation-related discontinuations were higher at the top dose, which can bias observed efficacy toward participants who tolerated the drug well — a pattern worth flagging in any topline efficacy citation.
Finally, none of these are network meta-analyses; they are individual randomized trials with different sponsors, statistical analysis plans, and endpoint definitions. A pooled or indirect-comparison meta-analysis with formal statistical adjustment for these differences has not yet been published as of this writing for the three-way comparison specifically.
Dosing, Titration, and Monitoring Considerations
Semaglutide for type 2 diabetes is typically titrated from 0.25 mg weekly to a maintenance dose of 1-2 mg weekly over several months, per FDA-approved labeling, to reduce GI adverse events during initiation. Tirzepatide follows a similar stepped approach, starting at 2.5 mg weekly and titrating in 2.5 mg increments to a maximum studied dose of 15 mg weekly.
Retatrutide's Phase 2 protocol used a comparable slow-titration design, though the trial tested doses up to 12 mg with titration schedules extending across multiple months to manage tolerability. Investigators noted that slower titration reduced but did not eliminate the GI symptom burden at higher doses.
Monitoring parameters referenced in pivotal trial protocols and product labeling for approved compounds include:
- Baseline and periodic renal function testing, particularly relevant given GI fluid losses in patients with reduced renal reserve
- Lipase and amylase monitoring in patients with a history of pancreatitis, though routine monitoring in the absence of symptoms is not universally recommended in labeling
- Heart rate tracking, since GLP-1 receptor agonists are associated with a modest mean increase of 2-4 beats per minute
- Gallbladder symptom screening, given a documented association between rapid weight loss and cholelithiasis risk
Because retatrutide remains investigational, no FDA-approved monitoring protocol exists for it outside of clinical trial settings, and any current human use occurs strictly under research or trial protocols rather than approved prescribing.
Where the Evidence Base Is Still Incomplete
Several gaps limit how confidently clinicians and researchers can rank these therapies against each other. No completed Phase 3 trial has directly randomized participants with type 2 diabetes to semaglutide versus retatrutide with cardiovascular or renal outcomes as a primary endpoint. Long-term cardiovascular outcome data comparable to SELECT (semaglutide) or SURPASS-CVOT (tirzepatide, ongoing) simply does not yet exist for triple agonists.
Durability beyond 72 weeks is another open question. Weight regain after discontinuation has been documented for semaglutide (STEP 1 extension data showed substantial regain within a year of stopping), but equivalent post-discontinuation data for retatrutide has not been published in a peer-reviewed, adequately powered trial as of this writing.
Sub-population signals also remain underexplored. Effect-size differences by baseline BMI, age, renal function, and concurrent insulin or sulfonylurea use are reported in subgroup analyses within individual trials but have not been synthesized across compounds. Clinicians managing patients at the margins of these subgroups — elderly patients, those with moderate renal impairment, or those on concurrent insulin — are extrapolating from thinner evidence than the topline efficacy numbers suggest.
Practical Considerations When Evaluating These Compounds
For a clinician or researcher assessing where a patient or study protocol fits into this landscape, a few practical distinctions are worth holding onto. Regulatory status differs sharply: semaglutide and tirzepatide are FDA-approved for type 2 diabetes (and, in specific formulations, for chronic weight management), while retatrutide and other multi-agonist peptides remain investigational, meaning they are appropriately accessed only through clinical trial enrollment, not through unregulated research-chemical channels.
Cost and access dynamics also diverge substantially by payer and formulation, though that landscape shifts frequently enough that current benefit-verification with a specific payer is more reliable than any published figure. Formulary status, prior-authorization requirements, and manufacturer savings programs all affect real-world access independent of the underlying trial data.
For research use specifically, sourcing and handling considerations differ meaningfully between an FDA-approved, pharmacy-dispensed product and an investigational compound obtained outside a trial protocol — the latter carries no verified purity, sterility, or dosing-accuracy assurance, which is a separate and material safety consideration from the pharmacology discussed above.
A Concrete Next Step
Anyone evaluating GLP-1 monoagonist versus multi-receptor agonist therapy for a specific patient or research protocol should start by confirming exactly which compound and receptor profile is under discussion — not the marketing label attached to it — then review the primary trial publication for that specific compound rather than relying on secondary summaries. The NEJM publications for STEP 1, SURPASS-2, SURMOUNT-1, and the retatrutide Phase 2 trial are all indexed on PubMed with full methods and adverse-event tables, and are the appropriate starting point before any prescribing or protocol decision is finalized with a licensed clinician.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.